Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20843832 | 0.80 | KDM1A (0.83) | KDM1A | |
| SCHEMBL20657193 | 0.79 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20672931 | 0.76 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20595006 | 0.75 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20657217 | 0.73 | KDM1A (1.00) | KDM1A | |
| SCHEMBL20595127 | 0.73 | KDM1A (1.00) | KDM1A | |
| SCHEMBL22359880 | 0.71 | KDM1A (0.71) | KDM1A | |
| SCHEMBL20595104 | 0.68 | KDM1A (0.51) | KDM1A | |
| SCHEMBL21423319 | 0.67 | KDM1A (0.60) | KDM1A | |
| SCHEMBL20604614 | 0.67 | KDM1A (0.60) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3642195-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2020-04-29 | — | — | EP | disclosed |
| CN-111032641-A | Substituted 5-cyanoindole compounds and uses thereof | 诺华股份有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| WO-2018234978-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | KDM1A, KDM5A, KDM1B | KDM1A 1/4885 |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | KDM1A, KDM5A, KDM1B | KDM1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.